Chauhan and colleagues designed AOS that target the β-secretase cleavage site of APP and found that by administrating it into a mouse model of AD, the soluble APPα increased by 43%, and the soluble Aβ40 and Aβ42 levels decreased by 39% [156]. The gene discussed is APP; the disease is Alzheimer disease.